The Society Citation is a discretionary award given in recognition of exemplary contributions to IDSA, an outstanding discovery in the field of infectious diseases or a lifetime of outstanding achievement. More than one award may be given each year.
John Brooks, MD
Martin S. Hirsch, MD, FIDSA
Matifadza Hlatshwayo Davis, MD, MPH
H. Clifford Lane, MD, FIDSA
John Brooks, MD, has been on the frontlines of the response to the COVID-19 pandemic by CDC and IDSA. He has also led or participated in CDC’s response to Ebola, Zika, Hurricane Katrina, SARS and anthrax.
As the chief medical officer for CDC’s COVID-19 Emergency Response, Dr. Brooks serves as a subject matter expert who assists leaders on the response team in staying updated on the latest treatment and prevention science related to COVID-19. He is known for his ability to rapidly synthesize and interpret data from multiple sources to inform the public health response. Dr. Brooks is also the chief medical officer of CDC’s Division of HIV/AIDS Prevention, where he advises division leaders on the medical aspects of HIV infection, including the planning and execution of Ending the HIV Epidemic in the U.S., a 2019 presidential initiative.
In past positions at CDC, Dr. Brooks served as the task force leader for CDC’s Ebola Response Unit and as team leader for CDC’s response units for Zika, Hurricane Katrina, SARS and anthrax. His work in these positions included supervising team members, overseeing surveillance and management efforts, producing reports and summaries for Morbidity and Mortality Weekly Report
and engaging in communication activities. Dr. Brooks has assisted CDC staff with congressional briefings and acted as CDC’s local liaison with the U.S. Congress, the State Department, the Central Intelligence Agency and other government agencies.
During the pandemic, Dr. Brooks provided emerging information to help inform the Society’s response, including information used in developing IDSA’s COVID-19 guidelines. Dr. Brooks held meetings with IDSA leaders and CDC and conveyed input from IDSA on providers’ experiences in managing COVID-19 to CDC. Also, he participated in four calls with clinicians from IDSA about COVID-19. Despite the demands on his time, Dr. Brooks answered late-night calls and urgent emails from IDSA leaders and members and maintained an upbeat attitude laced with much-needed humor.
Dr. Brooks is chair of the Tuberculosis Clinical Trials Consortium Data Safety Monitoring Board and a member of the AIDS Clinical Trials Group’s Co-Infection and Malignancy Work Group and the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents.
Dr. Brooks has received multiple commendations and awards. These include five outstanding unit commendations from DHHS, two awards for distinguished service and a distinguished service medal from CDC, and several awards for excellent or outstanding journal articles. IDSA is pleased to recognize Dr. Brooks’ contributions to public health with a 2022 Society Citation Award.
Martin S. Hirsch, MD, FIDSA, expertly guided IDSA’s The Journal of Infectious Diseases as editor-in-chief for 20 years, improving the quality of the articles, adapting to the increased focus on online content and offering more diversified content by publishing many supplements. He is a world-renowned and prolific virologist whose research on HIV helped transform a once fatal disease into a treatable condition.
Dr. Hirsch was a faculty member at Harvard Medical School and the Harvard School of Public Health for 45 years, serving most recently as a professor of immunology and infectious diseases at the Harvard School of Public Health. He is a senior physician at Massachusetts General Hospital and an associate member of the Ragon Institute of Massachusetts General Hospital, MIT and Harvard. The Ragon Institute brings together scientists and engineers from diverse fields to harness the immune system to prevent and cure human disease.
While skillfully guiding JID through changes in research and medical publishing, Dr. Hirsch also focused on improving the experience of authors and expanding the supplement program. He recruited guest editors to publish on topics such as “Triumphs of Vaccination.”
During the COVID-19 pandemic, Dr. Hirsch postponed his planned retirement from the role of editor-in-chief. In 2020, submissions to JID increased from 1,900 to an all-time high of 3,479, and readership increased by 48%. Readership in 2021 was 30% above 2019 levels. JID papers were discussed in Congress and in the pages of The New York Times. Having supported his editorial team with wit, humility and grace during this difficult time, Dr. Hirsch will be retiring as editor-in-chief as of Dec. 31, 2022.
Dr. Hirsch was the first investigator to test antiretroviral drug combinations in vitro, which underpinned the clinical trials that revolutionized HIV therapy. Also, he was the first to demonstrate that HIV could be isolated from both the male and female genital tracts. Dr. Hirsch has published nearly 250 peer-reviewed articles and co-authored 11 clinical guidelines and reports.
The chair of the NIAID HIV/AIDS Clinical Trials Network Strategic Working Group, Dr. Hirsch has also served as chair of NIH’s AIDS Clinical Trials Group, the largest research network of clinical trial sites in the world, and has chaired NIH HIV Vaccine Data Safety Monitoring Boards.
Throughout his career, Dr. Hirsch has given generously to trainees, faculty, the infectious diseases research world, JID and IDSA. His colleagues have profound respect and admiration for him. Dr. Hirsch has trained many of today’s leaders in virology and HIV medicine, who consider him a kind and most thoughtful mentor.
For his leadership of JID and his transformational research on HIV, IDSA is delighted to recognize Dr. Hirsch with a 2022 Society Citation Award.
Matifadza Hlatshwayo Davis, MD, MPH is a public health leader and a clinician-educator who focuses on HIV and COVID-19 in marginalized populations. Dr. Hlatshwayo Davis co-leads a global partnership in St. Louis to end the HIV epidemic. She is passionate about patient care; community engagement; and diversity, equity and inclusion initiatives.
Dr. Hlatshwayo Davis is the director of health for the St. Louis Department of Health, where she has championed equity by developing COVID-19 diagnosis and treatment programs, coordinating mobile COVID-19 testing and vaccine units and engaging local faith communities. She is also a member of the infectious diseases faculty and the lead HIV clinician at the John Cochran VA Medical Center.
Before joining the St. Louis Department of Health in 2021, Dr. Hlatshwayo Davis was a clinical instructor and associate program director of the fellowship program at Washington University School of Medicine’s Department of Infectious Diseases. Also, she was a faculty leader in the Department of Inclusion and Diversity.
As the former co-chair of Fast Track Cities St. Louis, Dr. Hlatshwayo Davis was leading work to end the HIV epidemic. Fast Track Cities St. Louis is a global partnership between elected officials, public health leaders and affected communities to end the HIV epidemic by 2030. Dr. Hlatshwayo Davis established a dashboard for HIV in St. Louis for the partnership and developed a standard approach for rapidly starting antiretroviral therapy in people with HIV.
Dr. Hlatshwayo Davis curates resources related to responding to health disparities in the management of COVID-19 as associate editor of the Disparities and Competent Care section of the COVID-19 Real-Time Learning Network. The network is a CDC and IDSA repository for the latest clinical guidance, protocols, clinical trials data, practice tools and resources on COVID-19.
As an expert on HIV and COVID-19 in marginalized populations, Dr. Hlatshwayo Davis is often featured on CNN, BBC, Al Jazeera, MSNBC and Newsweek and by other media. She frequently serves as an invited speaker on HIV prevention and treatment.
For her work in public health; HIV and COVID-19 in marginalized populations; and diversity, equity and inclusion initiatives, IDSA is proud to honor Dr. Hlatshwayo Davis with a 2022 Society Citation Award.
H. Clifford Lane, MD, FIDSA, is a physician-scientist at NIH who has made seminal contributions to the field of infectious diseases in HIV, emerging infectious diseases and COVID-19. Dr. Lane has made major contributions to understanding HIV pathophysiology, treating HIV-related complications and pioneering antiretroviral therapy. Behind the scenes, he has created clinical trials networks for HIV, Ebola and COVID-19.
Over 43 years at NIH’s NIAID, Dr. Lane is known for making things happen and for advocating within the government for sound science and sound policy. Currently, he is director of the Division of Clinical Research and deputy director for Clinical Research and Special Projects.
Dr. Lane is the rare physician-scientist who is equally adept at conducting elegant laboratory research and diplomatically navigating the complexities of leading clinical trials on a global scale. He co-founded the NIH AIDS research program and conducted basic research that demonstrated how aberrant immune activation causes the deficiency that is central to AIDS. He led more than 30 clinical trials, including pivotal research that transformed HIV from a fatal infection into a manageable chronic disease. Also, he led the first U.S. clinical trial of a candidate HIV vaccine and initiated the NIH Antiretroviral Treatment Guidelines, which are considered the gold standard for therapy.
By pioneering clinical trials networks and partnerships across five continents, Dr. Lane has facilitated emerging infectious diseases research and helped other countries build their own research capacity and infrastructure. He created an HIV clinical research infrastructure within the military in South Africa and, during the 2014-2016 West Africa Ebola outbreak, he led a research partnership between NIAID and Liberia, which conducted clinical trials of experimental Ebola vaccines and therapies. During the 2018-2020 Ebola outbreak, Dr. Lane formed a research partnership with the Democratic Republic of Congo. A pivotal clinical trial conducted through this partnership identified the first two Ebola therapies to receive FDA approval.
During the COVID-19 pandemic, Dr. Lane facilitated the NIH-led Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership, which developed a coordinated research strategy for prioritizing and speeding development of the most promising treatments and vaccines. Dr. Lane also co-chaired the NIH COVID-19 Treatment Guidelines Panel, which developed the COVID-19 Treatment Guidelines used by clinicians worldwide.
Dr. Lane conducts rigorous clinical research that adheres to the highest ethical standards, even during a global outbreak. He has published more than 450 journal articles. Dr. Lane has been a member of the IDSA Research Committee since 2004 and initiated the joint IDSA-NIAID research program for fellows.
IDSA is pleased to honor Dr. Lane with a 2022 Society Citation Award for his work in HIV, emerging infectious diseases and COVID-19 and for his development of important clinical trials networks.
Past Society Citation Award Winners
Dial Hewlett, Jr., MD, FIDSA
|2020||Adarsh Bhimraj, M.D., FIDSA|
|2020||Christopher A. Ohl, M.D., FIDSA|
|2019||Brian S. Schwartz, MD|
|Steven K. Schmitt, MD, FIDSA|
|2018||Louis D. Saravolatz, MD, FIDSA|
|2017||Wendy S. Armstrong, MD, FIDSA
Patrick Joseph, MD, FIDSA
Dean, L. Winslow, MD, FIDSA
|2016||Mark A. Leasure
Bruce G. Gellin, MD, MPH, FIDSA
Martin G. Myers, MD, FIDSA, FPIDS
|2015||Helen W. Boucher, MD, FIDSA|
|2014||David L. Thomas MD, MPH, FIDSA|
|2013||Marguerite A. Neill, MD
Catherine M. Wilfert, MD
|2012||Myron S. Cohen, MD, FIDSA
N. Cary Engleberg, MD, FIDSA
Alan D. Tice, MD, FIDSA, FSHEA
Carol J. Baker, MD, FIDSA
John G. Bartlett, MD, FIDSA
|2009||Warren D. Johnson, Jr., MD, FIDSA|
|2008||Russell Petrak, MD|
Gary P. Wormser, MD, FIDSA
Larry J. Strausbaugh, MD, FIDSA
George G. Jackson, MD
Stanley Falkow, PhD
|2003||Morton N. Swartz, MD
Julie Gerberding, MD, on behalf of the CDC staff
|2002||Marvin Turck, MD
C. Douglas Webb, PhD
|2001||George W. Counts, MD|
|2000||Dennis George Maki, MD
Dennis L. Stevens, MD, PhD
|1999||Sydney Finegold, MD|
|1998||Porter Anderson, PhD
John Robbins, MD
Rachel Schneerson, MD
David Smith, MD
|1997||Johan Septimus Bakken, MD|
|1996||Donald A. Henderson, MD|
|1995||King Holmes, MD, PhD|
|1994||David Rogers, MD
Edward Hook, III, MD
|1993||Dorothy Horstmann, MD
Samuel Katz, MD
Harold Neu, MD
|1992||Robert Austrian, MD
Jay Sanford, MD
|1988||Martha Yow, MD|
|1987||Margaret Pittman, PhD, MS|
|1986||Victor Nussenzweig, MD|
|1985||Robert Gallo, MD
Luc Montagnier, CNRS
Sheldon Wolff, MD
|1984||Allen Steere, MD|
|1983||Maurice Hilleman, PhD
Saul Krugman, MD
|1982||James Todd, MD|
|1981||Don Brenner, MS, PhD
William Cherry MS, PhD and Colleagues
James Freeley, PhD
Joseph McDade, PhD
|1977||Edward Kass, MD, PhD, M|